Table of Contents Author Guidelines Submit a Manuscript
Table of Contents Alerts

To receive news and publication updates for Case Reports in Rheumatology, enter your email address in the box below.

Case Reports in Rheumatology
Volume 2016 (2016), Article ID 7906013, 4 pages
http://dx.doi.org/10.1155/2016/7906013
Case Report

Development of Eosinophilic Fasciitis during Infliximab Therapy for Psoriatic Arthritis

Richard Hariman,1 Payal Patel,1 Jennifer Strouse,1 Michael P. Collins,2 and Ann Rosenthal1

1Division of Rheumatology, Department of Medicine, Medical College of Wisconsin, 9200 W. Wisconsin Avenue, Milwaukee, WI 53226, USA
2Department of Neurology, Medical College of Wisconsin, 9200 W. Wisconsin Avenue, Milwaukee, WI 53226, USA

Received 1 March 2016; Accepted 24 April 2016

Academic Editor: Mario Salazar-Paramo

Copyright © 2016 Richard Hariman et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. I. Pinal-Fernandez, A. Selva-O'Callaghan, and J. M. Grau, “Diagnosis and classification of eosinophilic fasciitis,” Autoimmunity Reviews, vol. 13, no. 4-5, pp. 379–382, 2014. View at Publisher · View at Google Scholar · View at Scopus
  2. S. I. Wasserman, J. R. Seibold, T. A. Medsger Jr., and G. P. Rodnan, “Serum eosinophilotactic activity in eosinophilic fasciitis,” Arthritis and Rheumatism, vol. 25, no. 11, pp. 1352–1356, 1982. View at Publisher · View at Google Scholar · View at Scopus
  3. A. E. El-Shazly, V. Moonen, M. Mawet et al., “IFN-γ and TNF-α potentiate prostaglandin D2-induced human eosinophil chemotaxis through up-regulation of CRTH2 surface receptor,” International Immunopharmacology, vol. 11, no. 11, pp. 1864–1870, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. H. Kankaanranta, P. Ilmarinen, X. Zhang et al., “Tumour necrosis factor-α regulates human eosinophil apoptosis via ligation of TNF-receptor 1 and balance between NF-κB and AP-1,” PLoS ONE, vol. 9, no. 2, Article ID e90298, 2014. View at Publisher · View at Google Scholar
  5. R. Adamson, Y. Yazici, E. S. Katz, S. G. Greisman, and D. Steiger, “Fatal acute necrotizing eosinophilic myocarditis temporally related to use of adalimumab in a patient with relapsing polychondritis,” Journal of Clinical Rheumatology, vol. 19, no. 7, pp. 386–389, 2013. View at Publisher · View at Google Scholar · View at Scopus
  6. N. Tugnet, A. Youssef, and A. J. Whallett, “Wells' syndrome (eosinophilic cellulitis) secondary to infliximab,” Rheumatology, vol. 51, no. 1, pp. 195–196, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. N. Shakoor, M. Michalska, C. A. Harris, and J. A. Block, “Drug-induced systemic lupus erythematosus associated with etanercept therapy,” The Lancet, vol. 359, no. 9306, pp. 579–580, 2002. View at Publisher · View at Google Scholar · View at Scopus
  8. D. Lebeaux, C. Francés, S. Barete et al., “Eosinophilic fasciitis (Shulman disease): new insights into the therapeutic management from a series of 34 patients,” Rheumatology, vol. 51, no. 3, pp. 557–561, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. D. Khanna, H. Agrawal, and P. J. Clements, “Infliximab may be effective in the treatment of steroid-resistant eosinophilic fasciitis: report of three cases,” Rheumatology, vol. 49, no. 6, Article ID keq062, pp. 1184–1188, 2010. View at Publisher · View at Google Scholar · View at Scopus